U.S. Capital Wealth Advisors LLC Takes Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 4th quarter, HoldingsChannel reports. The fund acquired 13,875 shares of the biotechnology company’s stock, valued at approximately $69,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp raised its stake in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after acquiring an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after buying an additional 295,864 shares in the last quarter. International Assets Investment Management LLC raised its stake in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after buying an additional 229,487 shares in the last quarter. Woodstock Corp raised its stake in Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock worth $973,000 after buying an additional 14,113 shares in the last quarter. Finally, Barclays PLC raised its stake in Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after buying an additional 48,313 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

ALDX stock opened at $5.93 on Friday. Aldeyra Therapeutics, Inc has a 1 year low of $2.71 and a 1 year high of $6.55. The firm has a 50-day moving average of $5.06 and a 200 day moving average of $5.11. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.25). As a group, equities research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.